Windtree Therapeutics is a biotechnology company that specializes in developing innovative KL4 surfactant therapies for respiratory diseases and other potential applications. With a focus on improving patient outcomes, Windtree is advancing late-stage interventions for acute cardiovascular disorders, providing hope and efficient treatment during critical moments. Their portfolio includes a multi-asset franchise built around compounds that activate SERCA2a, with istaroxime being the lead candidate for acute heart failure and cardiogenic shock.

Furthermore, Windtree's heart failure platform encompasses oral pre-clinical SERCA2a activator assets. One notable product in their portfolio is rostafuroxin, a precision drug targeting treatment-resistant hypertension in patients with specific genetic profiles. By leveraging new scientific and clinical approaches, Windtree aims to address significant unmet medical needs and deliver responsible critical care innovations.

With an unwavering commitment to quality and access to care, Windtree Therapeutics is dedicated to transforming patient outcomes in crisis situations